ジスキネジア市場：タイプ別、治療法別、投与経路別、エンドユーザー別-2025-2030年の世界予測

ジスキネジア市場は、2023年に23億4,000万米ドルと評価され、2024年には25億米ドルに達すると予測され、CAGR 8.44％で成長し、2030年には41億3,000万米ドルになると予測されています。

ジスキネジアは、パーキンソン病や類似の疾患と関連することが多く、筋肉の不随意、不規則、身動きのとれない動きを指します。その範囲は、主にレボドパのような薬剤の長期使用に関連する薬剤誘発性のジスキネジアを含む、幅広い疾患に及ぶ。ジスキネジアに対処する必要性は、患者のQOLに大きな影響を与えることから生じており、調査と治療が不可欠です。応用範囲には、主に神経伝達系を標的とする医薬品や症状緩和を提供する治療機器が含まれます。主な最終用途分野には、病院、診療所、研究機関などがあります。市場成長の原動力は、神経疾患の有病率の上昇、認知度の向上、医療技術の進歩です。しかし、治療費の高騰や既存の治療法に伴う副作用が成長の大きな課題となっています。個別化医療と遺伝子治療の革新は有望な発展の道を提供し、市場力学に大きな影響を与える可能性があります。現在の治療機会は、非ドパミン作動性治療オプションの開発と、リアルタイムで症状を追跡するためのウェアラブル・モニタリング技術にあります。企業にとっては、最先端の治療を開拓するために研究機関と積極的にパートナーシップを結び、AI主導の研究戦略を実施することが有利に働く可能性があります。新しい治療法の有効性と安全性を実証するために、包括的な臨床試験に投資することが重要な推奨事項です。規制のハードルや厳しい承認プロセスといった課題は、新規治療法の市場参入をしばしば遅らせる。さらに、治療に対する患者の反応の不均一性から、より個別化されたアプローチが必要となり、標準化の努力が複雑になる可能性があります。治療法の地理的な格差は、新興市場での普及の重要性を強調しています。技術革新に最適な分野としては、神経保護戦略や神経変性に影響を及ぼす微生物と腸の相互作用の解明などが挙げられます。全体として、ジスキネジア市場は、特に新たなイノベーションが既存の限界に対処することで成長する態勢が整っているが、潜在能力をフルに発揮するためには、固有の複雑性と課題を戦略的に克服する必要があります。

市場力学：急速に進化するジスキネジア市場の主要市場インサイトを公開

ジスキネジア市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 製薬企業と研究機関の協力関係
  • 患者中心の治療モデルの増加による治療アドヒアランスと治療成績の向上
  • ジスキネジアの治療における低侵襲手術技術への高い需要
  • ジスキネジア症状の緩和を目的とした新規治療薬のパイプラインの拡大
• 市場抑制要因
  • 先進治療にかかる費用の高さ
• 市場機会
  • ジスキネジア患者の運動能力と生活の質を高める革新的な治療介入
  • ジスキネジアの早期発見と進行モニタリングのための高度な診断ツールおよび技術
  • ジスキネジア管理のための薬理学的および非薬理学的アプローチを統合した個別化治療計画
• 市場の課題
  • 厳しい規制要件に伴う副作用

ポーターの5つの力：ジスキネジア市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ジスキネジア市場における外部からの影響の把握

外部マクロ環境要因は、ジスキネジア市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ジスキネジア市場における競合情勢の把握

ジスキネジア市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスジスキネジア市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ジスキネジア市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ジスキネジア市場における成功への道筋を描く

ジスキネジア市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬企業と調査機関の連携
    • 治療の遵守と成果を向上させる患者中心のケアモデルの増加
    • 治療のための低侵襲手術技術に対する高い需要ジスキネジア
    • ジスキネジア症状の緩和を目的とした新規治療薬のパイプラインの拡大
  • 抑制要因
    • 高度な治療にかかる高額な費用
  • 機会
    • ジスキネジア患者の運動機能と生活の質を向上させる革新的な治療介入
    • ジスキネジアの進行を早期に検出し監視するための高度な診断ツールとテクノロジー
    • ジスキネジア管理のための薬理学的アプローチと非薬理学的アプローチを統合した個別治療計画
  • 課題
    • 厳しい規制要件と薬の副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ジスキネジア市場：タイプ別

• 舞踏病
• レボドパ誘発性ジスキネジア
• ミオクローヌス
• 口腔顔面ジスキネジア
• 発作性ジスキネジア
• 遅刻ジスキネジア

第7章 ジスキネジア市場治療別

• 医薬品
  • 抗コリン薬
  • グルタミン酸ブロッカー
  • モノアミン輸送修飾剤
• 外科手術
  • アブレーション技術
  • 脳深部刺激療法
• 治療法
  • 作業療法
  • 理学療法
  • 言語療法

第8章 ジスキネジア市場：投与経路別

• 注射可能
• オーラル
• 経皮パッチ

第9章 ジスキネジア市場：エンドユーザー別

• 学術調査機関
• ホームケア
• 病院
• 専門クリニック

第10章 南北アメリカのジスキネジア市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のジスキネジア市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのジスキネジア市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. AbbVie Inc.
• 2. Acadia Pharmaceuticals Inc.
• 3. Acorda Therapeutics, Inc.
• 4. Adamas Pharmaceuticals, Inc.
• 5. Amneal Pharmaceuticals, Inc.
• 6. BioArctic AB
• 7. GlaxoSmithKline plc
• 8. Intra-Cellular Therapies, Inc.
• 9. Ipsen Pharma
• 10. Kyowa Kirin Co., Ltd.
• 11. Lundbeck A/S
• 12. Medtronic plc
• 13. Merz Pharmaceuticals GmbH
• 14. Neurocrine Biosciences, Inc.
• 15. Roche Holding AG
• 16. Sage Therapeutics, Inc.
• 17. Sunovion Pharmaceuticals Inc.
• 18. Teva Pharmaceutical Industries Ltd.
• 19. Ultragenyx Pharmaceutical Inc.
• 20. Voyager Therapeutics, Inc.

LIST OF FIGURES

• FIGURE 1. DYSKINESIA MARKET RESEARCH PROCESS
• FIGURE 2. DYSKINESIA MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DYSKINESIA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DYSKINESIA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DYSKINESIA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DYSKINESIA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL DYSKINESIA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DYSKINESIA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DYSKINESIA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DYSKINESIA MARKET DYNAMICS
• TABLE 7. GLOBAL DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DYSKINESIA MARKET SIZE, BY LEVODOPA-INDUCED DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DYSKINESIA MARKET SIZE, BY OROFACIAL DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DYSKINESIA MARKET SIZE, BY PAROXYSMAL DYSKINESIAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DYSKINESIA MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DYSKINESIA MARKET SIZE, BY GLUTAMATE BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DYSKINESIA MARKET SIZE, BY MONOAMINE TRANSPORT MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DYSKINESIA MARKET SIZE, BY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DYSKINESIA MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DYSKINESIA MARKET SIZE, BY SPEECH THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DYSKINESIA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL DYSKINESIA MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL DYSKINESIA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. CANADA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CANADA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. CANADA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 63. CANADA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 64. CANADA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 65. CANADA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. CANADA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES DYSKINESIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. AUSTRALIA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. CHINA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. CHINA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. CHINA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 100. CHINA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 101. CHINA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 102. CHINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. CHINA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. INDIA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. INDIA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 106. INDIA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 107. INDIA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 108. INDIA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 109. INDIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. INDIA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. INDONESIA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. JAPAN DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. MALAYSIA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. PHILIPPINES DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. SINGAPORE DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. SOUTH KOREA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. TAIWAN DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. THAILAND DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. VIETNAM DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. DENMARK DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. EGYPT DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 202. FINLAND DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. FRANCE DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 216. GERMANY DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 223. ISRAEL DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 224. ITALY DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 225. ITALY DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 226. ITALY DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 227. ITALY DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 228. ITALY DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 229. ITALY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. ITALY DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 237. NETHERLANDS DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 244. NIGERIA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 251. NORWAY DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 252. POLAND DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 253. POLAND DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 254. POLAND DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 255. POLAND DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 256. POLAND DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 257. POLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 258. POLAND DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 259. QATAR DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 260. QATAR DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 261. QATAR DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 262. QATAR DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 263. QATAR DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 264. QATAR DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 265. QATAR DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 272. RUSSIA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 278. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 279. SAUDI ARABIA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 286. SOUTH AFRICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 292. SPAIN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 293. SPAIN DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 299. SWEDEN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 300. SWEDEN DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 306. SWITZERLAND DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 307. SWITZERLAND DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 312. TURKEY DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 313. TURKEY DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 314. TURKEY DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 319. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 320. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 321. UNITED ARAB EMIRATES DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 324. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 325. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
• TABLE 326. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 327. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 328. UNITED KINGDOM DYSKINESIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 329. DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 330. DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2023

The Dyskinesia Market was valued at USD 2.34 billion in 2023, expected to reach USD 2.50 billion in 2024, and is projected to grow at a CAGR of 8.44%, to USD 4.13 billion by 2030.

Dyskinesia, often associated with Parkinson's disease and similar disorders, refers to involuntary, erratic, and writhing movements of muscles. Its scope covers a wide range of conditions, including drug-induced dyskinesia primarily linked to long-term use of medications like levodopa. The necessity for addressing dyskinesia arises from its significant impact on patients' quality of life, making research and treatment imperative. The application scope primarily includes pharmaceuticals targeting neurotransmitter systems and therapeutic devices offering symptom relief. Key end-use sectors include hospitals, clinics, and research institutions. Market growth is driven by rising prevalence of neurological disorders, increasing awareness, and advancements in medical technology. However, the high cost of treatment and side effects associated with existing therapies pose significant growth challenges. Innovations in personalized medicine and gene therapy offer promising avenues for development and could significantly impact market dynamics. Present opportunities lie within the development of non-dopaminergic treatment options and wearable monitoring technology for real-time symptom tracking. For businesses, actively engaging in partnerships with research institutions to pioneer cutting-edge treatments and implementing AI-driven research strategies could prove advantageous. A crucial recommendation is investing in comprehensive clinical trials to substantiate the efficacy and safety of new interventions. Challenges like regulatory hurdles and stringent approval processes often slow down market entry of novel therapies. Furthermore, the heterogeneity of patient responses to treatment necessitates more personalized approaches, which can complicate standardization efforts. Geographic disparities in treatment availability underscore the importance of expanding reach in emerging markets. The best areas for innovation include neuroprotective strategies and the exploration of microbiome-gut interactions affecting neurodegeneration. Overall, the dyskinesia market is poised for growth, particularly as new innovations address existing limitations, yet it requires strategic navigation of the inherent complexities and challenges to realize full potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dyskinesia Market

The Dyskinesia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Collaborative efforts between pharmaceutical companies and research institutions
  • Increase in patient-centric care models enhancing treatment adherence and outcomes
  • High demand for minimally invasive surgical techniques for treating dyskinesia
  • Expanding pipeline of novel therapeutic agents aimed at mitigating dyskinesia symptoms
• Market Restraints
  • High costs of advanced treatments
• Market Opportunities
  • Innovative therapeutic interventions for enhancing mobility and quality of life in dyskinesia patients
  • Advanced diagnostic tools and technologies for early detection and monitoring of dyskinesia progression
  • Personalized treatment plans integrating pharmacological and non-pharmacological approaches for dyskinesia management
• Market Challenges
  • Adverse medication effects along with stringent regulatory requirements

Porter's Five Forces: A Strategic Tool for Navigating the Dyskinesia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dyskinesia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dyskinesia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dyskinesia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dyskinesia Market

A detailed market share analysis in the Dyskinesia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dyskinesia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dyskinesia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dyskinesia Market

A strategic analysis of the Dyskinesia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dyskinesia Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Acadia Pharmaceuticals Inc., Acorda Therapeutics, Inc., Adamas Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., BioArctic AB, GlaxoSmithKline plc, Intra-Cellular Therapies, Inc., Ipsen Pharma, Kyowa Kirin Co., Ltd., Lundbeck A/S, Medtronic plc, Merz Pharmaceuticals GmbH, Neurocrine Biosciences, Inc., Roche Holding AG, Sage Therapeutics, Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Ultragenyx Pharmaceutical Inc., and Voyager Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Dyskinesia Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Chorea, Levodopa-Induced Dyskinesia, Myoclonus, Orofacial Dyskinesia, Paroxysmal Dyskinesias, and Tardive Dyskinesia.
• Based on Treatment, market is studied across Medications, Surgical Procedures, and Therapies. The Medications is further studied across Anticholinergics, Glutamate Blockers, and Monoamine Transport Modifiers. The Surgical Procedures is further studied across Ablative Techniques and Deep Brain Stimulation. The Therapies is further studied across Occupational Therapy, Physical Therapy, and Speech Therapy.
• Based on Route of Administration, market is studied across Injectable, Oral, and Transdermal Patches.
• Based on End User, market is studied across Academic & Research Institutes, Homecare, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Collaborative efforts between pharmaceutical companies and research institutions
    • 5.1.1.2. Increase in patient-centric care models enhancing treatment adherence and outcomes
    • 5.1.1.3. High demand for minimally invasive surgical techniques for treating dyskinesia
    • 5.1.1.4. Expanding pipeline of novel therapeutic agents aimed at mitigating dyskinesia symptoms
  • 5.1.2. Restraints
    • 5.1.2.1. High costs of advanced treatments

• 5.1.3. Opportunities
  • 5.1.3.1. Innovative therapeutic interventions for enhancing mobility and quality of life in dyskinesia patients
  • 5.1.3.2. Advanced diagnostic tools and technologies for early detection and monitoring of dyskinesia progression
  • 5.1.3.3. Personalized treatment plans integrating pharmacological and non-pharmacological approaches for dyskinesia management
• 5.1.4. Challenges
  • 5.1.4.1. Adverse medication effects along with stringent regulatory requirements

• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dyskinesia Market, by Type

• 6.1. Introduction
• 6.2. Chorea
• 6.3. Levodopa-Induced Dyskinesia
• 6.4. Myoclonus
• 6.5. Orofacial Dyskinesia
• 6.6. Paroxysmal Dyskinesias
• 6.7. Tardive Dyskinesia

7. Dyskinesia Market, by Treatment

• 7.1. Introduction
• 7.2. Medications
  • 7.2.1. Anticholinergics
  • 7.2.2. Glutamate Blockers
  • 7.2.3. Monoamine Transport Modifiers
• 7.3. Surgical Procedures
  • 7.3.1. Ablative Techniques
  • 7.3.2. Deep Brain Stimulation
• 7.4. Therapies
  • 7.4.1. Occupational Therapy
  • 7.4.2. Physical Therapy
  • 7.4.3. Speech Therapy

8. Dyskinesia Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Oral
• 8.4. Transdermal Patches

9. Dyskinesia Market, by End User

• 9.1. Introduction
• 9.2. Academic & Research Institutes
• 9.3. Homecare
• 9.4. Hospitals
• 9.5. Specialty Clinics

10. Americas Dyskinesia Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Dyskinesia Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Dyskinesia Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Acadia Pharmaceuticals Inc.
• 3. Acorda Therapeutics, Inc.
• 4. Adamas Pharmaceuticals, Inc.
• 5. Amneal Pharmaceuticals, Inc.
• 6. BioArctic AB
• 7. GlaxoSmithKline plc
• 8. Intra-Cellular Therapies, Inc.
• 9. Ipsen Pharma
• 10. Kyowa Kirin Co., Ltd.
• 11. Lundbeck A/S
• 12. Medtronic plc
• 13. Merz Pharmaceuticals GmbH
• 14. Neurocrine Biosciences, Inc.
• 15. Roche Holding AG
• 16. Sage Therapeutics, Inc.
• 17. Sunovion Pharmaceuticals Inc.
• 18. Teva Pharmaceutical Industries Ltd.
• 19. Ultragenyx Pharmaceutical Inc.
• 20. Voyager Therapeutics, Inc.